CYBRD1: A Potential Drug Target for Xenobiotics and Metabolites

Target Name: CYBRD1

NCBI ID: G79901

CYBRD1

CYBRD1: A Potential Drug Target for Xenobiotics and Metabolites

CYBRD1, also known as Ferric-chelate Reductase 3, is a gene that encodes a protein involved in the detoxification of environmental toxins and xenobiotics in the body. The encoded protein is a member of the superfamily of NAD+-dependent enzymes, which are involved in various cellular processes that depend on the levels of NAD+.

CYBRD1 is expressed in most tissues and cells of the body and is involved in the detoxification of a wide variety of xenobiotics, including environmental toxins, such as polychlorinated biphenyls (PCBs), polycyclic aromatic hydrocarbons (PAHs), and other potentially harmful substances found in the environment.

The function of CYBRD1 is to convert the toxic xenobiotics into less toxic forms that can be eliminated from the body. This process involves a series of steps, including the reduction of the xenobiotics to their less toxic metabolites.

The first step in the detoxification process is the conversion of xenobiotics to their corresponding metabolites. This is typically done through the action of CYBRD1, which is a xenobiotic reducing enzyme. In the CYBRD1 enzyme system, xenobiotics are reduced to their metabolites, which are then excreted from the body.

CYBRD1 is also involved in the detoxification of certain metabolites of other drugs that are toxic to the body. For example, CYBRD1 has been shown to be involved in the detoxification of the chemotherapy drug doxorubicin, which is commonly used to treat various types of cancer.

In addition to its role in detoxification, CYBRD1 is also a potential drug target. Researchers are interested in using CYBRD1 as a target for new drugs because of its unique mechanism of action and its potential to modulate a wide range of cellular processes.

One of the reasons why CYBRD1 is an attractive drug target is its location in the genome. CYBRD1 is located on chromosome 19, which makes it a potential target for small molecules that can be used to modulate the activity of the enzyme. In addition, CYBRD1 is a gene that is highly conserved across different species, which suggests that it is a good candidate for targeting with small molecules.

Another reason why CYBRD1 is a potential drug target is its role in the detoxification process. As mentioned earlier, CYBRD1 is involved in the detoxification of a wide variety of xenobiotics, which makes it an attractive target for drugs that can modulate the detoxification process. This could lead to a more efficient and effective treatment of a wide range of diseases.

In addition to its potential as a drug target, CYBRD1 is also a potential biomarker. The detoxification of xenobiotics is a critical process that is involved in the overall health and well-being of the body. Therefore, changes in the levels of CYBRD1 activity could be an important indicator of the health and status of the body.

Research into the role of CYBRD1 in the detoxification process has the potential to lead to the development of new treatments for a wide range of diseases. For example, CYBRD1 may be a useful target for cancer treatments because of its involvement in the detoxification of chemotherapy drugs. Additionally, CYBRD1 may be a potential target for other diseases, such as neurodegenerative disorders, where the detoxification of harmful substances is impaired.

In conclusion, CYBRD1 is a gene that encodes a protein involved in the detoxification of environmental toxins and xenobiotics in the body. It is a member of the superfamily of NAD+-dependent enzymes and is expressed in most tissues and cells of the body. The function

Protein Name: Cytochrome B Reductase 1

Functions: Plasma membrane reductase that uses cytoplasmic ascorbate as an electron donor to reduce extracellular Fe(3+) into Fe(2+) (PubMed:30272000). Probably functions in dietary iron absorption at the brush border of duodenal enterocytes by producing Fe(2+), the divalent form of iron that can be transported into enterocytes (PubMed:30272000). It is also able to reduce extracellular monodehydro-L-ascorbate and may be involved in extracellular ascorbate regeneration by erythrocytes in blood (PubMed:17068337). May also act as a ferrireductase in airway epithelial cells (Probable). May also function as a cupric transmembrane reductase (By similarity)

The "CYBRD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYBRD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets